{"classes":[{"categories":[{"measurements":[{"comment":"Median and upper CI was not estimable due to insufficient number of events.","groupId":"OG000","lowerLimit":"18.5","upperLimit":"NA","value":"NA"},{"groupId":"OG001","lowerLimit":"5.6","upperLimit":"8.2","value":"6.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"261"},{"groupId":"OG001","value":"263"}],"units":"Participants"}],"description":"Progression-free survival (PFS) by BICR was defined as the time from the date of enrollment to the earlier of the dates of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause. Progressive disease was defined as at least a 20% increase in the sum of diameters of target lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with HER2-positive, unresectable and/or metastatic breast cancer participants previously treated with trastuzumab and taxane who received T-DXd as a sterile intravenous (IV) solution at a dose of 5.4 mg/kg every 3 weeks (Q3W).","id":"OG000","title":"Trastuzumab Deruxtecan (T-DXd)"},{"description":"Participants with HER2-positive, unresectable and/or metastatic breast cancer participants previously treated with trastuzumab and taxane who received T-DM1 in accordance with the approved label.","id":"OG001","title":"Ado-trastuzumab Emtansine (T-DM1)"}],"paramType":"MEDIAN","populationDescription":"Progression-free survival (PFS) was assessed in the Full Analysis Set at data cut-off date of 21 May 2021.","reportingStatus":"POSTED","timeFrame":"Up to 33 months (data cut-off)","title":"Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane","type":"PRIMARY","unitOfMeasure":"months"}